Figure 6:

Antitumor efficacy study of VERU-111 in A549 and A549/TxR animal models. Athymic nude mice received 7.5 mg/kg or 12.5 mg/kg oral dose (po) of VERU-111 every five days in a week and 12.5 mg/kg paclitaxel intraperitoneal (ip) injection for three alternate days in a week. The drug treatment was started when the tumor volume reached to 100 mm3 and indicated at day 0 in these graphs. (A) A549 xenografted mice showed significant inhibition of tumor growth in all treated groups. (B) There was no significant change in body weight. (C) The weight of the tumors also significantly lower than control. (D) The photograph of individual tumors from all groups. (E) Xenograft study showing A549/TxR resistant tumor volume after treatment with various treatment groups. Cisplatin was injected at a dose of 5 mg/kg ip once in a week. The combination group received 12.5 mg/kg po of VERU-111 and 5 mg/kg ip of cisplatin. (F) Only cisplatin therapy alone or in combination with VERU-111 showed slight reduction of mice body weight. (G) The quantitative analysis of the tumor weight from different groups. (H) The tumor photographs showing no response in tumor size in control and paclitaxel group. Data represented as the mean ± SEM (n=5–7). Statistical analysis was performed by Dunnett multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus control or indicated.